TAS-102 an Emerging Oral Fluoropyrimidine.
Australia. In Anticancer Res, Jan 2016
Various approaches have been used to improve the efficacy of 5-FU including inhibition of its degradation enzyme dihydropyrimidine dehydrogenase (DPD) such as S1, UTF, use of 5-FU pro-drug capecitabine to exploit thymidine phosphorylase (TP) and supplementation of reduced folate acid to increase cytotoxicity.
TAS-102, a novel antitumor agent: A review of the mechanism of action.
Los Angeles, United States. In Cancer Treat Rev, Nov 2015
TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD.
Thymidine Phosphorylase in Cancer; Enemy or Friend?
Dublin, Ireland. In Cancer Microenviron, Sep 2015
UNASSIGNED: Thymidine phosphorylase (TP) is a nucleoside metabolism enzyme that plays an important role in the pyrimidine pathway.TP catalyzes the conversion of thymidine to thymine and 2-deoxy-α-D-ribose-1-phosphate (dRib-1-P).